IRAKM Recombinant Antibody

$Western blot analysis of A431 cell lysate. Using IRAKM (bsm-61264R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n$

Western blot analysis of A431 cell lysate. Using IRAKM (bsm-61264R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n

Applications

Reactivity

Human

Overview
Catalog #	bsm-61264r-100ul
Product Name	IRAKM Recombinant Antibody
Applications	WB, IP
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human IRAK3
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
Storage Condition	Shipped at 4°. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	11213
Swiss Prot	Q9Y616
Subcellular location	Cytoplasm
Synonyms	ASRT5; FLJ13601; IL-1 receptor-associated kinase M; Interleukin-1 receptor-associated kinase 3; interleukin-1 receptor-associated kinase M; IRAK-3; IRAK-M; IRAK3; IRAKM.
Background	Putative inactive protein kinase which regulates signaling downstream of immune receptors including IL1R and Toll-like receptors.Inhibits dissociation of IRAK1 and IRAK4 from the Toll-like receptor signaling complex by either inhibiting the phosphorylation of IRAK1 and IRAK4 or stabilizing the receptor complex.Upon IL33-induced lung inflammation, positively regulates expression of IL6, CSF3, CXCL2 and CCL5 mRNAs in dendritic cells.
Application Dilution
WB	1:300-5000
IP	1-2ug